Coronary Vasomotor Control in Obesity and Morbid Obesity Contrasting Flow Responses With Endocannabinoids, Leptin, and Inflammation by Quercioli, Alessandra et al.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 5 , N O . 8 , 2 0 1 2
© 2 0 1 2 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 2 . 0 1 . 0 2 0Coronary Vasomotor Control in Obesity
and Morbid Obesity
Contrasting Flow Responses With Endocannabinoids, Leptin,
and Inﬂammation
Alessandra Quercioli, MD,* Zoltan Pataky, MD,† Fabrizio Montecucco, MD,*
Sebastian Carballo, MD,‡ Aurélien Thomas, PHD,§ Christian Staub, PHD,§
Vincenzo Di Marzo, PHD, Gabriella Vincenti, MD,* Giuseppe Ambrosio, MD,¶
Osman Ratib, MD,# Alain Golay, MD,† François Mach, MD,* Elisabetta Harsch, MD,†
Thomas H. Schindler, MD*
Geneva, Switzerland; and Naples and Perugia, Italy
O B J E C T I V E S This study sought to investigate abnormalities in coronary circulatory function in 2
different disease entities of obese (OB) and morbidly obese (MOB) individuals and to evaluate whether these
would differ in severity with different proﬁles of endocannabinoids, leptin, and C-reactive protein (CRP)
plasma levels.
B A C KG ROUND There is increasing evidence that altered plasma levels of endocannabinoids,
leptin, and CRP may affect coronary circulatory function in OB and MOB.
METHOD S Myocardial blood ﬂow (MBF) responses to cold pressor test from rest and during
pharmacologically induced hyperemia were measured with N-13 ammonia positron emission tomog-
raphy/computed tomography. Study participants (n  111) were divided into 4 groups based on their
body mass index (BMI) (kg/m2): 1) control group (BMI: 20 to 24.9, n  30); 2) overweight group (BMI: 25
to 29.9, n  31), 3) OB group (BMI: 30 to 39.9, n  25); and 4) MOB group (BMI 40, n  25).
R E S U L T S The cold pressor test–induced change in endothelium-related MBF response (∆MBF) progres-
sively declined in overweight and OB groups when compared with the control group [median: 0.19
(interquartile range [IQR] 0.08, 0.27) and 0.11 (0.03, 0.17) vs. 0.27 (0.23, 0.38) ml/g/min; p 0.01, respectively],
whereas it did not differ signiﬁcantly between OB and MOB groups [median: 0.11 (IQR: 0.03, 0.17) and 0.09
(–0.01, 0.19) ml/g/min; p  0.93]. Compared with control subjects, hyperemic MBF subjects comparably
declined in the overweight, OB, and MOB groups [median: 2.40 (IQR 1.92, 2.63) vs. 1.94 (1.65, 2.30), 2.05 (1.67,
2.38), and 2.14 (1.78, 2.76) ml/g/min; p 0.05, respectively]. In OB individuals, ∆MBF was inversely correlated
with increase in endocannabinoid anandamide (r  –0.45, p  0.044), but not with leptin (r  –0.02, p 
0.946) or with CRP (r –0.33, p 0.168). Conversely, there was a signiﬁcant and positive correlation among
∆MBF and elevated leptin (r 0.43, p 0.031) and CRP (r 0.55, p 0.006), respectively, in MOB individuals
that was not observed for endocannabinoid anandamide (r  0.07, p  0.740).
CONC L U S I O N S Contrasting associations of altered coronary endothelial function with increases
in endocannabinoid anandamide, leptin, and CRP plasma levels identify and characterize OB and MOB
as different disease entities affecting coronary circulatory function. (J Am Coll Cardiol Img 2012;5:
805–15) © 2012 by the American College of Cardiology Foundation
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806s obesity has been recognized as a risk factor of
cardiovascular morbidity and mortality, the
worldwide global epidemic of obesity with
an increasing prevalence, not only in
adults but also among children and adolescents, has
raised major health concerns (1). Recent investiga-
tions have demonstrated a close association between
obesity and an abnormal function of the coronary
circulation (2,3), which is commonly regarded as a
functional precursor of the coronary artery disease
(CAD) process (4,5). Increasing attention has been
directed to a novel concept that plasma proteins
See page 816
originating from the adipose tissue, so-
called adipocytokines, such as adiponectin,
leptin, and/or endocannabinoids (EC) as
well as metabolically triggered inflamma-
tion may alter vascular function (6–8).
Whereas adiponectin has been widely ap-
preciated to beneficially affect nitric oxide–
mediated, endothelium-dependent vaso-
motion (6), the role of leptin altering
coronary circulatory function in humans
remains controversial (2). As regards the
role of EC in obesity, we have shown
recently that increases in EC plasma levels
such as of anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) are inversely
associated with coronary circulatory dys-
function in obese individuals (3). This
would suggest that elevated EC plasma
levels exert adverse effects on the function
of the coronary circulation (4). Systemic
inflammation also seems to play an impor-
tant role in altering coronary circulatory
function in cardiovascular risk individuals
(9,10). Conversely, its role in affecting the
function of the coronary circulation in
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obese individuals (BMI: 30 kg/m2) without arte-
ial hypertension, smoking, and diabetes mellitus
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807electrocardiogram, blood pressure measurements,
and routine blood chemistry in a fasting state.
Physical examination revealed normal findings in all
applicants and they had normal resting electrocar-
diograms. Each study participant then underwent
dual x-ray absorptiometry (Hologic QDR4500A,
Hologic, Bedford, Massachusetts) to measure body
composition, total fat amount burden, and fat
distribution as described previously (12). Subse-
quently, N-13 ammonia positron emission tomog-
raphy (PET)/computed tomography (CT) mea-
surements of myocardial blood flow (MBF) at rest
and during vasomotor stress were performed in a
fasting state to assess coronary circulatory function.
Twenty-one control (CON), 26 OW, 17 OB, and
13 MOB subjects were part of a previous investi-
gation assessing the effect of elevated EC plasma
levels in obesity on coronary circulatory function
(3). Routine blood chemistry of EC such as AEA and
2-AG, leptin and adiponectin plasma levels were
determined (3). The study was approved by the
University Hospitals of Geneva Institutional Review
Board (No. 07-183), and each participant signed the
Table 1. Characteristics of Study Population (N  111)
CON
(n  30)
O
(n 
BMI, kg/m2 21.9 (20.7, 22.9) 26.7 (25
Waist/hip ratio 0.85 (0.81, 0.89) 0.90 (0.
Waist, cm 83.0 (80.0, 85.0) 98.0 (92
Total fat amount, g 12,872 (10,509, 15,961) 20,341.0 (17
Percentage of body fat 19.7 (14.8, 26.1) 23.6 (21
Android/gynoid fat mass 0.89 (0.80, 1.18) 1.43 (1.
Central fat distribution 0.40 (0.38, 0.45) 0.48 (0.
Age, yrs 40 (30, 46) 44 (33
Female/male 9/12 11
AEA, ng/ml 0.56 (0.49, 0.71) 0.52 (0.
2-AG, ng/ml 1.50 (0.60, 5.47) 1.40 (0.
Adiponectin, g/ml 3.78 (2.3, 5.4) 3.25 (1.
Leptin 5.47 (2.3, 11.2) 12.66 (8.
Lipid status
Cholesterol levels, mg/dl 191 (168, 230) 207 (17
LDL level, mg/dl 122 (105, 145) 129 (11
HDL level, mg/dl 58 (41, 66) 46 (39
Triglyceride level, mg/dl 54 (48, 101) 93 (67
Glucose level, mg/dl 93 (82, 101) 97 (88
Insulin, mUI/l 3.2 (1.9, 5.2) 6.1 (3.
HOMA 0.7 (0.44, 1.03) 1.4 (0.
hsCRP levels, mg/l 0.9 (0.9, 3.0) 1.0 (0.
HbAlc, % 5.2 (4.9, 5.5) 5.2 (5.
Values are median (Q1, Q3). Central fat distribution is calculated as trunk fat m
2-AG 2-arachidonoylglycerol; AEA anandamide; BMI body mass index; C
Model Assessment; hsCRP  high-sensitivity C-reactive protein; LDL  low-denapproved informed consent form.Assessment of coronary artery calciﬁcation and myo-
cardial perfusion with PET/CT. Prior to PET flow
studies, we used 64-slice multidetector computed
tomography of the Biograph HiRez TruePoint
PET/CT scanner (Siemens, Erlangen, Germany)
to determine coronary artery calcium score (13).
Following, myocardial perfusion was determined
with N-13 ammonia PET/CT (3). In all study
participants, visual evaluation and polar map
analysis of the N-13 ammonia distribution at rest
and during vasomotor stress revealed homoge-
neous tracer uptake. In addition, MBF was de-
termined in ml/g/min from serial transaxial N-13
ammonia PET/CT image acquisition in conjunc-
tion with a 2-compartment tracer kinetic model
(3). N-13 ammonia PET/CT determined left-
ventricular MBFs at rest, then during the cold
pressor test (CPT), and during pharmacologically
induced hyperemia with standard infusion of
dipyridamole (140 mg/kg/min) (3,4). Heart rate,
blood pressure, and a 12-lead electrocardiogram
were recorded continuously during each MBF
measurement. From the average of heart rate and
)
p
Value
OB
(n  25)
p
Value
M
(n 
8.2) 0.0001 31.7 (31.0, 34.9) 0.0001 45.0 (43.
.93) 0.019 0.94 (0.91, 0.98) 0.0001 0.97 (0.8
103.0) 0.0001 111.0 (106.0, 117.5) 0.0001 124.0 (116
, 23,628) 0.0001 29,310 (27,328, 35,281) 0.0001 60,871 (50,
8.3) 0.008 29.7 (28.5, 31.4) 0.0001 47.8 (40.
.89) 0.001 1.59 (1.42, 1.83) 0.0001 1.69 (1.1
.54) 0.001 0.52 (0.50, 0.56) 0.0001 0.56 (0.4
) 0.159 44 (36, 57) 0.158 42 (35,
8/17 10
.67) 0.267 0.65 (0.50, 0.73) 0.179 0.70 (0.5
.09) 0.605 1.92 (1.21, 2.66) 0.755 2.67 (1.3
.27) 0.430 2.76 (0.5, 4.5) 0.250 2.11 (0.4
5.84) 0.001 16.03 (9.4, 22.9) 0.001 110.50 (59.
30) 0.723 211 (172, 226) 0.533 187 (158
52) 0.401 122 (99, 152) 0.899 119 (103
) 0.010 44 (37, 49) 0.008 42 (39,
0) 0.012 123 (95, 191) 0.0001 122 (83,
3) 0.150 97 (92, 108) 0.020 103 (96,
.9) 0.004 8.1 (5.2, 10.6) 0.001 28.6 (17.
8) 0.008 1.9 (1.2, 3.9) 0.0001 8.3 (4.5
0) 0.847 2.9 (1.4, 5.2) 0.008 8.0 (4.9
4) 0.961 5.4 (5.0, 5.7) 0.338 5.45 (5.4
otal body fat mass  100. P values versus CON (Mann-Whitney U test for indep
control subjects; HbAlc glycosylated hemoglobin; HDL high-density lipoprote
lipoprotein; MOB  morbid obesity; OB  obesity; OW  overweight; Q  quarW
31
OB
25)
p
Value
.9, 2 2, 47.5) 0.0001
85, 0 4, 1.06) 0.010
.62, .0, 140.2) 0.0001
,323 090, 66,404) 0.0001
.5, 2 9, 50.7) 0.0001
12, 1 9, 2.19) 0.0001
43, 0 6, 0.61) 0.0001
, 51 54) 0.233
/19 /15
42, 0 8, 0.77) 0.002
72, 2 7, 5.23) 0.576
67, 5 , 3.6) 0.041
04, 2 8, 147.5) 0.0001
0, 2 , 213) 0.960
1, 1 , 137) 0.969
, 55 46) 0.017
, 12 167) 0.0001
, 10 118) 0.011
3, 10 3, 38.1) 0.0001
7, 2. , 13.2) 0.0001
9, 2. , 13.0) 0.0001
0, 5. , 5.7) 0.008
ass/t endent samples).
ON in; HOMA Homeostasissystolic blood pressure during the first 2 min of
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808each image acquisition, the rate-pressure product
(RPP) was derived as an index of cardiac work.
To account for possible interindividual variations
in coronary driving pressure, an index of global
coronary vascular resistance (CVR) was deter-
mined as the ratio of mean arterial blood pressure
(mm Hg) to MBF (ml/g/min). In addition, MBF
was normalized to the RPP, and thus myocardial
work (averaged during the first 2 min of image
acquisition; MBF divided by RPP multiplied by
103) was determined.
Statistical analysis. Because continuous variables are
ot always normally distributed, they are presented
s median and interquartile range (25th to 75th
ercentile: quartile 1, quartile 3). For comparison of
ifferences, we used the Mann-Whitney U test for
ndependent samples (SAS Institute, Cary, North
arolina). A comparison of CPT-induced change
n MBF and dipyridamole MBFs among the dif-
erent groups was performed by 1-way analysis of
ariance (ANOVA) followed by Scheffe multiple
omparison test. Pearson correlation coefficients (r),
ssuming a linear regression and the standard error of
he estimate (SEE), were calculated to investigate the
ssociations between CPT- and dipyridamole-
nduced changes in MBFs and laboratory parame-
ers. Multivariate analysis was performed with step-
ise forward regression of variables with significance
n univariate analysis. All test procedures were
-tailed, and p  0.05 was considered statistically
ignificant.
Table 2. Entire Study Population
Leptin, ng/ml Adiponectin
Waist, cm r 0.54 r –0
p 0.0001 p 0.1
Waist/hip ratio r 0.17 r –0
p 0.168 p 0.0
BMI, kg/m2 r 0.69 r –0
p 0.0001 p 0.0
Total fat amount, g r 0.73 r –0
p 0.0001 p 0.0
Percentage of body fat r 0.75 r –0
p 0.0001 p 0.1
Trunk fat amount, g r 0.74 r –0
p 0.0001 p 0.0
Central fat distribution r 0.27 r –0
p 0.010 p 0.0
Android/gynoid fat mass r 0.12 r –0
p 0.258 p 0.0
Central fat distribution  trunk fat mass/total fat mass  100. Android/gynoid
Abbreviations as in Table 1.R E S U L T S
Patient characteristics and metabolic proﬁle. The
clinical characteristics, anthropometrical measure-
ments, and dual x-ray absorptiometry–determined
total fat amount burden and fat distribution of the
study groups are given in Table 1. For the entire
study population, coronary artery calcification
(CAC) was found in 14% (15 of 111). In the CON
group, the prevalence of CAC was 17% (5 of 30)
with a coronary artery calcium score of 6.8  6.7.
Conversely, in the OW, OB, and MOB groups
only 12% (4 of 31), 16% (4 of 25), and 8% (2 of 25)
had CAC with coronary artery calcium score of
96.5  94.4, 11.9  9.2, and 57.7  27.4, respec-
tively. Regarding the CAC distribution, the highest
prevalence was in the left anterior descending artery
(n  14), followed by the right coronary (n  7)
and left circumflex (n  5) arteries, respectively.
Correlations among fat parameters, EC, and adipocyto-
kines. In the entire study population, Pearson re-
ression analysis denoted a significant correlation
etween BMI and total fat amount as estimated by
ual x-ray absorptiometry (r  0.95; p  0.0001).
ignificant and positive correlations were noted
mong BMI, total fat, percentage of body fat, or
runk fat amount and leptin, AEA, and hsCRP,
espectively, whereas they correlated inversely with
diponectin (Table 2). Further, central fat distribu-
ion, as the trunk fat and total fat ratio, was
ignificantly associated with leptin and AEA and
g/ml AEA, ng/ml 2-AG, ng/ml hsCRP, mg/l
r 0.16 r 0.16 r 0.31
p 0.240 p 0.220 p 0.013
r 0.24 r 0.24 r 0.08
p 0.043 p 0.040 p 0.479
r 0.35 r 0.14 r 0.54
p 0.0001 p 0.167 p 0.0001
r 0.33 r 0.13 r 0.59
p 0.001 p 0.207 p 0.0001
r 0.21 r 0.09 r 0.62
p 0.034 p 0.390 p 0.0001
r 0.41 r 0.19 r 0.49
p 0.0001 p 0.068 p 0.0001
r 0.32 r 0.14 r 0.06
p 0.001 p 0.175 p 0.596
r 0.37 r 0.17 r 0.07
p 0.0001 p 0.108 p 0.537
ass  trunk fat amount/leg fat amount., 
.20
33
.24
43
.29
03
.23
19
.15
35
.27
08
.23
25
.21
44
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809inversely with adiponectin. As regards the android/
gynoid fat mass distribution, it significantly corre-
lated with AEA and inversely with adiponectin.
The waist circumference was significantly associ-
ated with leptin and hsCRP, whereas the waist/hip
ratio correlated inversely with adiponectin and pos-
itively with AEA and 2-AG, respectively. As re-
gards the OB group, only central fat distribution
and android/gynoid fat mass ratio were inversely
correlated with leptin (r  –0.58; p  0.011 and
r  –0.53; p  0.024), whereas android/gynoid fat
mass ratio also correlated positively with AEA (r 
0.51; p  0.030). In the MOB group again, there
were significant associations among total fat
amount and AEA (r  0.52; p  0.011) and 2-AG
(r  0.45; p  0.031), whereas percentage of body
fat correlated with leptin (r  0.43; p  0.035) and
hsCRP (r  0.62; p  0.002), respectively. Also,
trunk fat amount correlated with adiponectin (r 
Table 3. MBF and Hemodynamic Findings During PET/CT Exam
CON OW
MBF, ml/min/g
MBF at rest 0.69 (0.65, 0.75) 0.70 (0.62
NMBF at rest 0.92 (0.85, 1.13) 0.96 (0.83
MBF during CPT 1.00 (0.89, 1.18) 0.86 (0.78
∆MBF to CPT from rest 0.27 (0.23, 0.38) 0.19 (0.08
NMBF during CPT 1.05 (0.92, 1.15) 0.93 (0.84
MBF during hyperemia 2.40 (1.92, 2.63) 1.94 (1.65
MFR 3.40 (2.97, 3.82) 2.88 (2.31
MBF hyperemia/NMBF rest 2.33 (1.94, 2.70) 1.93 (1.57
CVR, mm Hg/ml/min/g
At rest 117 (102, 134) 130 (116,
During CPT 96 (76, 110) 117 (99, 1
Change to CPT from rest 23 (33,15) 9 (31
Pharmacologic vasodilation 33 (27, 39) 43 (35, 5
Hemodynamics at rest
Heart rate, beats/min 62 (54, 70) 63 (55, 6
SBP, mm Hg 114 (103, 123) 120 (113,
RPP 6,788 (6,159, 7,756) 7,134 (6,52
CPT
Heart rate, beats/min 72 (64, 83) 69 (60, 7
SBP, mm Hg 134 (122, 141) 136 (127,
RPP 9,098 (8,511, 1,0913) 9,525 (8,34
∆RPP, CPT-rest 2,448 (1,811, 3,270) 1,902 (1,32
Pharmacologic vasodilation
Heart rate, beats/min 84 (73, 92) 84 (80, 9
SBP, mm Hg 111 (103, 118) 117 (111,
RPP 8,901 (8,129, 10,375) 9,840 (8,69
∆RPP, pharmacologic-rest 1,887 (1,013, 2,668) 2,147 (1,54
Values are median (Q1, Q3). p values versus CON (Mann-Whitney U test for ind
CPT cold pressor test; CT computed tomography; CVR coronary vascularﬂow; PET  positron emission tomography; RPP  rate-pressure product; SBP  sy0.43; p  0.047), AEA (r  0.65; p  0.001), and
2-AG (r  0.66; p  0.001), respectively. Finally,
there were also significant associations among an-
droid/gynoid fat mass distributions and leptin (r 
0.49; p  0.020), and 2-AG (r  0.48; p  0.023).
Hemodynamic parameters. At baseline, heart rate
id not differ significantly among the CON, OW,
nd OB groups, but it was significantly higher in
he MOB group (Table 3). Systolic blood pressure
SBP) among groups was comparable. Due to the
igher heart rate in the MOB group, however, the
esting RPP was significantly higher in the MOB
ubjects than in CON and OW subjects, whereas it
id not differ significantly between the OB and
OB groups. Sympathetic stimulation with CPT
nduced a significant increase in heart rate and SBP
mong groups, so that the RPP was significantly
igher during CPT than at baseline. The increase
n the RPP (RPP) as a result of the CPT-induced
Groups
p Value OB p Value MOB
6) 0.761 0.68 (0.57, 0.79) 0.914 0.83 (0.71,
9) 0.332 0.88 (0.78, 1.03) 0.250 0.98 (0.90,
4) 0.026 0.75 (0.71, 0.90) 0.0001 0.93 (0.81,
7) 0.005 0.11 (0.03, 0.17) 0.0001 0.09 (0.0
6) 0.053 0.78 (0.71, 0.87) 0.0001 0.77 (0.71,
) 0.006 2.05 (1.67, 2.38) 0.014 2.14 (1.78,
7) 0.007 3.15 (2.36, 3.28) 0.050 2.53 (2.13,
2) 0.055 2.18 (1.26, 2.76) 0.012 2.04 (1.76,
) 0.045 119 (109, 149) 0.357 104 (94, 12
0.002 132 (117, 151) 0.0001 119 (99, 13
0.049 6 (9, 13) 0.0001 7 (4, 1
0.001 43 (37, 50) 0.001 43 (37, 55
0.928 66 (57, 73) 0.408 67 (66, 74
) 0.051 122 (106, 133) 0.233 120 (110, 1
024) 0.440 7,488.0 (6,738, 9,021) 0.140 8,284 (7,293
0.206 72 (62, 77) 0.456 76 (70, 84
) 0.324 148 (126, 156) 0.088 148 (141, 1
,764) 0.908 9,450 (8,628, 11,503) 0.597 11,376 (10,29
951) 0.148 1,786 (1,336, 3,279) 0.597 3,096 (1,840
0.669 87 (81, 95) 0.461 95 (83, 10
) 0.031 120 (111, 129) 0.010 120 (118, 1
,998) 0.125 10,512 (9,366, 11,538) 0.013 11,880 (10,43
738) 0.349 2,392 (1,648, 4,051) 0.297 3,324 (2,035
dent samples).
tance; MBFmyocardial blood ﬂow; MFRmyocardial ﬂow reserve; NMBF norp Value
, 0.7 0.98) 0.003
, 1.0 1.17) 0.382
, 1.0 1.08) 0.141
, 0.2 1, 0.19) 0.0001
, 1.0 0.98) 0.001
, 2.3 2.42) 0.053
, 3.2 2.76) 0.0001
, 2.5 2.40) 0.0001
138 8) 0.099
34) 8) 0.001
, 4) 8) 0.0001
0) ) 0.002
8) ) 0.006
128 32) 0.201
7, 8, , 8,964) 0.003
8) ) 0.224
148 58) 0.003
0, 10 3, 12,528) 0.003
9, 2, , 4,075) 0.285
1) 2) 0.065
122 31) 0.002
2, 10 8, 12,365) 0.0001
9, 3, , 4,314) 0.109
epen
resis malized myocardial bloodstolic blood pressure; other abbreviations as in Table 1.
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810sympathetic stimulation was not significantly dif-
ferent among the CON, OW, OB, and MOB
subjects (Table 3), signifying comparable increases
in myocardial workload among the study groups.
During pharmacologic vasodilation with dipyri-
damole to induce hyperemic flows, the heart rate
significantly increased among study groups, whereas
SBP mildly decreased in the CON, OW, and OB
groups and remained unchanged in the MOB
group. The change in RPP (RPP) during dipyri-
damole stimulation was comparable among the
study groups (Table 3).
Myocardial blood ﬂow. At baseline, MBF was com-
arable among the CON, OW, and OB groups, but
t was significantly higher in the MOB group
Table 3). When adjusted for RPP, the normalized
BF at rest did not differ significantly among
roups. The endothelium-related change of MBF
uring CPT from rest (MBF to CPT) and the
ormalized MBF during CPT were significantly
ess in the OW, OB, and MOB groups than in the
ON group, whereas they were comparable be-
ween the OB and MOB groups, respectively (Table 3).
he group comparison between the MBF to CPT
nd normalized MBF during CPT in CON sub-
ects was significant as compared with OW, OB,
nd MOB subjects, respectively (p  0.0001 by
NOVA). In addition, changes of CVR widely
Figure 1. N-13 Ammonia PET/CT Perfusion Images
Example of a normal stress and rest myocardial perfusion study on
emission tomography (PET)/computed tomography (CT) in a 55-yea
versely, the myocardial ﬂow reserve (MFR  myocardial blood ﬂow
ment of the coronary vasodilatory capacity.irrored those of MBF for each study group (Table 3).
hus, differences in hemodynamic responses can be
idely ruled out as a possible cause for the observed
lteration in MBF during CPT.
Dipyridamole-stimulated hyperemic MBFs were
ignificantly lower in OW, OB, and MOB subjects
han in CON subjects (Table 3, Fig. 1). The MFR,
r total coronary vasodilator capacity, declined from
he CON group to the OW and OB groups, but
as comparable between the OW and OB groups.
n addition, the MFR was significantly less in the
OB group than in the CON, OW, and OB
roups, respectively. The group comparison of di-
yridamole MBFs and MFR in the CON group
as significantly different from those in the OB and
OB groups (p  0.015 and p  0.002 by
NOVA). The CVR during dipyridamole stimu-
ation, accounting for possible interindividual vari-
tions in coronary driving pressure, was significantly
igher in the OW, OB, and MOB groups than in
he CON group and thus confirmed the reduced
asodilatory capacity in individuals with increasing
ody weight (Table 3). Also here, the group com-
arison of CVR during dipyridamole stimulation in
he CON group was significantly different from
hose in the OW, OB, and MOB groups (p 
.002 by ANOVA).
rt-, horizontal-, and vertical-axis images of N-13 ammonia positron
morbidly obese woman (body mass index: 43 kg/m2). Con-
F] stress/MBF rest) of 1.91 is mildly reduced, signifying an impair-sho
r-old
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811Determinants of MBF to CPT and hyperemic MBF. In
he entire study population, on univariate analysis
ge, total fat amount, sex, AEA, 2-AG, SBP, and
riglyceride plasma levels were inversely, whereas
DL cholesterol was positively correlated with
ndothelium-related changes in MBF from rest to
PT (MBF) (Table 4). By multivariate analysis,
nly total fat amount and sex remained indepen-
ently associated with MBF (beta: –0.380 [95%
onfidence interval (CI): 0.0001 to 0.0001]; p 
.001, and beta: –0.338 [95% CI: –0.212 to
0.046], p  0.003). Further, hyperemic MBFs
orrelated inversely with age, sex, AEA, and 2-AG,
ut positively with HDL cholesterol plasma levels,
espectively. Conversely, only age, sex, and 2-AG
lasma levels proved to be independently associated
ith hyperemic MBFs, respectively (beta: –0.234
95% CI: –0.018 to –0.002], p  0.016; beta:
0.202 [95% CI: –0.408 to –0.007]; p  0.043,
nd beta: –0.194 [95% CI: –1.061 to 0.009]; p 
.054).
As regards the OB group, the univariate analysis
emonstrated sex, AEA, and 2-AG plasma levels as
ell as SBP to be significantly and inversely asso-
iated with MBF (Table 5, Fig. 2A). By multi-
ariate analysis, only 2-AG plasma levels were
ndependently associated with MBF (beta: –0.484
95% CI: –0.021 to –0.001]; p  0.030). Further,
nivariate analysis showed hyperemic MBFs to be
ignificantly associated only with 2-AG plasma
evels. Conversely, the univariate analysis in MOB
Table 4. Entire Study Population
MBF to CPT
Coefﬁcient Beta (95% CI)
Age, yrs 0.202 (0.006 to 0.0001)
Total fat amount, g 0.370 (0.0001 to 0.0001)
Male 0.252 (0.164 to0.024)
AEA, ng/ml 0.295 (0.483 to0.104)
2-AG, ng/ml 0.220 (0.018 to0.001)
Adiponectin, g/ml 0.171 (0.002 to 0.024)
Leptin, ng/ml 0.152 (0.001 to 0.0001)
SBP, mm Hg 0.203 (0.006 to 0.0001)
Total cholesterol, mg/dl 0.080 (0.001 to 0.001)
LDL cholesterol, mg/dl 0.107 (0.002 to 0.001)
HDL cholesterol, mg/dl 0.239 (0.001 to 0.005)
Triglycerides, mg/dl 0.295 (0.001 to 0.0001)
Glucose, mg/dl 0.098 (0.002 to 0.001)
HOMA 0.200 (0.020 to 0.001)
hsCRP, mg/l 0.114 (0.009 to 0.002)
p values determined by analysis of variance.
CI  conﬁdence interval; other abbreviations as in Tables 1 and 3.Table 5, Fig. 2B) demonstrated leptin and hsCRP
lasma levels to be significantly and positively
ssociated with MBF. By multivariate analysis,
nly increases in hsCRP plasma levels were associ-
ted with MBF in an independent fashion (beta:
.522 [95% CI: 0.002 to 0.013]; p  0.014).
egarding the hyperemic MBFs, they correlated
ith total fat amount, sex, SBP, HDL cholesterol,
nd hsCRP plasma levels, respectively, whereas on
ultivariate analysis only sex was independently
ssociated with MBFs during dipyridamole stimu-
ation (beta: –0.459 [95% CI: –0.691 to –0.061];
 0.022).
D I S C U S S I O N
The results of the current study provide several new
findings. At first, there was a progressive decrease in
endothelium-dependent MBF responses to CPT
from normal weight CON subjects to OW and OB
subjects, whereas it did not differ significantly be-
tween the OB and MOB groups. In addition,
hyperemic MBFs were comparably altered among
groups with increases in body weight. Thus, despite
marked increases in body weight from OB to MOB
subjects, there was no further progressive worsening
of coronary circulatory function. Secondly, increases
in EC plasma levels of AEA and 2-AG were
inversely associated with an impairment of coronary
endothelial function in OB subjects, which is sug-
Univariate Analysis
Hyperemic MBF
p Value Coefﬁcient Beta (95% CI) p Value
0.037 0.286 (0.020 to0.004) 0.003
0.0001 0.074 (0.0001 to 0.0001) 0.457
0.009 0.299 (0.496,0.116) 0.002
0.003 0.234 (1.165 to0.106) 0.019
0.028 0.210 (0.048 to0.002) 0.037
0.087 0.177 (0.004 to 0.067) 0.078
0.128 0.038 (0.002 to 0.002) 0.704
0.036 0.147 (0.014 to 0.002) 0.133
0.424 0.026 (0.002 to 0.003) 0.797
0.297 0.034 (0.003 to 0.002) 0.740
0.015 0.278 (0.003 to 0.015) 0.004
0.003 0.095 (0.002 to 0.001) 0.346
0.322 0.095 (0.005 to 0.002) 0.340
0.074 0.098 (0.043 to 0.017) 0.388
0.255 0.012 (0.015 to 0.017) 0.906
Abbreviations as in Table
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812gestive of adverse effects of ECs on the coronary
endothelium, but this association was not more
observed in MOB subjects. Thirdly, elevations in
leptin and hsCRP plasma levels were correlated
with endothelium-related MBF responses to CPT
in the MOB group, although positively, whereas
there was no such association in the OB group.
Increases in leptin and hsCRP plasma levels there-
fore were associated with relatively higher, though
diminished, endothelium-mediated MBF increases
to CPT in the MOB group, stressing some bene-
ficial effects on coronary endothelial function.
These contrasting associations of altered coronary
endothelial function with increases in AEA, leptin,
and hsCRP plasma levels, however, confirm the
hypothesis that OB and MOB reflect 2 different
disease entities, rather than a simple continuation of
increases in body weight, affecting coronary circu-
latory function.
Metabolic proﬁle. As expected, total cholesterol and
low-density lipoprotein cholesterol were similar
among groups with increasing body weight (1).
Conversely, HDL cholesterol progressively de-
creased and triglyceride increased from CON sub-
jects to OW and OB subjects, but no further
alterations were noted between the OB and MOB
groups. When regarding plasma markers of the
insulin-resistance syndrome and chronic inflamma-
tion, they also continuously increased but across the
Morbid Obesity Groups
OB
MBF to CPT Hyperemic MBF
Coefﬁcient Beta
(95% CI)
p
Value
Coefﬁcient Beta
(95% CI)
p
Val
0.27 (0.008 to 0.002) 0.257 0.31 (0.034 to 0.007) 0.1
0.12 (0.0001 to 0.0001) 0.625 0.27 (0.0001 to 0.0001) 0.2
0.46 (0.498 to 0.009) 0.043 0.32 (1.723 to 0.353) 0.1
0.45 (0.660 to0.010) 0.044 0.18 (2.503 to 0.961) 0.4
0.63 (0.023 to0.005) 0.004 0.46 (0.080 to 0.001) 0.0
0.005 (0.026 to 0.026) 0.985 0.02 (0.098 to 0.105) 0.9
0.02 (0.007 to 0.006) 0.946 0.10 (0.031 to 0.021) 0.6
0.51 (0.009 to0.001) 0.021 0.11 (0.025 to 0.016) 0.6
l 0.18 (0.002 to 0.001) 0.462 0.01 (0.006 to 0.006) 0.9
0.24 (0.002 to 0.001) 0.344 0.03 (0.006 to 0.006) 0.9
l 0.05 (0.005 to 0.007) 0.838 0.21 (0.014 to 0.033) 0.4
0.08 (0.001 to 0.001) 0.740 0.06 (0.004 to 0.003) 0.8
0.02 (0.002 to 0.002) 0.950 0.10 (0.009 to 0.006) 0.6
0.11 (0.037 to 0.024) 0.657 0.04 (0.117 to 0.133) 0.8
0.33 (0.022 to 0.004) 0.168 0.34 (0.087 to 0.016) 0.1
alysis of variance.
s 1, 3, and 4.whole spectrum of increasing body weight. Notably,apart from glucose plasma levels, there was a strik-
ing and nonlinear increase in insulin resistance,
plasma levels of insulin, and hsCRP from the OB to
MOB groups. Consequently, a marked increase of
body weight from the OB to MOB groups did not
further alter the lipid profile, HDL cholesterol, or
triglycerides, whereas plasma glucose levels were
only mildly affected. This observation can be ex-
plained by differences in adipose tissue distribution
and metabolic activity between the OB and MOB
groups. Visceral adipose tissue accumulation exerts
more deleterious metabolic effects than subcutane-
ous fat accumulation does, mainly due to the higher
fatty acid supply from the abdominal area, which
contributes to metabolic abnormalities (1). Con-
trary to intra-abdominal fat depots, subcutaneous
adipose tissue accumulation may be rather protec-
tive owing to a lower lipolytic response to cat-
echolamines, a higher antilipolytic sensitivity to
insulin, and an enhanced lipoprotein lipase activ-
ity (14). Also, distinct visceral adipose tissue,
such as round ligament and mesenteric adipose
tissues, which pose a higher sensibility to effects
of insulin in stimulating lipoprotein lipase activ-
ity and lipogenesis and in inhibiting lipolysis, is
likely to have contributed to reduced metabolic
effects at the expense of an increased fat accumu-
lation (1,14,15). This also provides a rationale
why plasma glucose levels were only slightly
MOB
MBF to CPT Hyperemic MBF
Coefﬁcient Beta
(95% CI)
p
Value
Coefﬁcient Beta
(95% CI)
p
Value
0.27 (0.008 to 0.002) 0.194 0.08 (0.019 to 0.024) 0.775
0.07 (0.0001 to 0.0001) 0.748 0.67 (0.0001 to 0.0001) 0.028
0.30 (0.194 to 0.029) 0.140 1.22 (1.379 to0.537) 0.002
0.07 (0.386 to 0.278) 0.740 0.17 (1.238 to 0.462) 0.293
0.26 (0.056 to 0.005) 0.224 0.19 (0.13 to 0.044) 0.223
0.33 (0.026 to 0.006) 0.112 0.19 (0.125 to 0.037) 0.220
0.43 (0.0001 to 0.002) 0.031 0.13 (0.005 to 0.003) 0.483
0.14 (0.007 to 0.004) 0.515 0.81 (0.017 to 0.041) 0.002
0.01 (0.001 to 0.001) 0.978 4.15 (0.053 to 0.135) 0.353
0.00 (0.002 to 0.002) 0.991 0.39 (0.012 to 0.003) 0.158
0.12 (0.004 to 0.007) 0.584 0.44 (0.026 to0.003) 0.022
0.23 (0.002 to 0.001) 0.298 0.22 (0.001 to 0.005) 0.171
0.29 (0.001 to 0.003) 0.183 0.19 (0.003 to 0.003) 0.347
0.12 (0.009 to 0.014) 0.612 0.13 (0.035 to 0.016) 0.396
0.55 (0.002 to 0.013) 0.007 0.34 (0.003 to 0.024) 0.020Table 5. Obesity and
ue
Age, yrs 90
Total fat amount, g 80
Male 82
AEA, ng/ml 55
2-AG, ng/ml 57
Adiponectin, g/ml 44
Leptin, ng/ml 98
SBP, mm Hg 54
Total cholesterol, mg/d 92
LDL cholesterol, mg/dl 15
HDL cholesterol, mg/d 01
Triglycerides, mg/dl 05
Glucose, mg/dl 29
HOMA 88
hsCRP, mg/l 63
p values determined by anhigher in MOB subjects than in OB subjects
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813despite a progressive increase in insulin plasma
levels and insulin resistance.
When looking specifically at EC and adiponec-
tin, plasma levels of EC mildly but progressively
increased, whereas adiponectin declined with in-
creases in body weight (1,3). Interestingly, the EC,
AEA, and 2-AG were positively, whereas adi-
ponectin plasma levels were inversely, associated
with the total fat amount but also with surrogate
markers for visceral adipose tissue burden such as
waist/hip ratio, central fat, and android/gynoid fat
distribution. Thus, apart from the total fat amount
increase, the visceral adipose tissue appears to re-
flect a predominant source of alterations in EC and
adiponectin plasma levels in individuals with in-
creasing body weight as reported previously (1,3).
The progressive decrease of adiponectin plasma
levels in obese individuals with increasing body
weight has been related to a state of metabolic stress
associated with increases in catecholamines, gluco-
corticoids, and insulin, which of all exert inhibitory
effects on the expression and release of adiponectin
from the adipose tissue (1). As regards leptin
plasma levels, they were significantly higher in OB
subjects than in CON and OW subjects (2). No-
tably, there was a 7-fold higher increase in leptin
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Figure 2. Relationships Among AEA, Leptin, Inﬂammation, and
Correlations among (A) anandamide (AEA), leptin, and high-sensitiv
related myocardial blood ﬂow (∆MBF) during cold pressor testing (C
morbid obesity group. SEE  standard error of the estimate.plasma levels in MOB subjects versus OB subjects.Plasma levels of leptin have been shown to correlate
more closely with total and subcutaneous tissue
than with visceral adipose tissue (1). For this
reason, circulating leptin plasma levels are generally
higher in women, who commonly develop more
subcutaneous fat than men do (1). In the current
study, the striking increase in leptin plasma levels
was correlated with the total percentage of body fat
and an android pattern of fat distribution in MOB
subjects, suggesting the increase in adipose tissue as
a whole and also visceral fat mass distribution as
predominant sources of the marked increase in
leptin plasma levels. This may be partly surprising
(1) but most likely is related to the lower prevalence
of women versus men in the MOB group.
Coronary circulatory function and interrelations.
When regarding the MFR or total coronary vaso-
dilator capacity, it significantly declined from the
CON to the OW group with a mild increase from
the OW to the OB group, whereas it was then
lowest in the MOB group. The relatively low MFR
in the MOB group was primarily related to the
augmentation in resting MBF induced by higher
resting heart rates, SBP, and resulting RPP, which
are indicative of the myocardial workload. This
finding also accords with previous investigations in
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-reactive protein (CRP) plasma levels and change of endothelium-
in the obese group, respectively, and (B) correspondingly in the to 
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814obesity (3,16). An increase in myocardial workload
in obese individuals, associated with higher resting
MBF, is commonly related to an activation of the
sympathetic nervous system and renin-angiotensin-
aldosterone system (16). Addressing specifically the
OB group, increases in EC such as AEA and 2-AG
plasma levels were inversely correlated with altera-
tions in coronary circulatory function. These find-
ings confirm and extend a recent report (3), empha-
sizing that, apart from effects related to obesity such
as low HDL cholesterol, insulin resistance, and
inflammation, increases in EC plasma levels play a
pivotal role in mediating coronary circulatory dys-
function in OB subjects. As mentioned before, we
did not observe a further worsening of coronary
circulatory function from OB to MOB subjects.
This somehow astounding observation may be sup-
ported by recent results in the assessment of bra-
chial artery function in severe obesity (11). Flow-
mediated and, thus, endothelium-dependent
vasodilation was paradoxically higher in severely
obese individuals than in obese and normal weight
individuals. This paradoxical preservation in flow-
mediated vasodilation in individuals with severe
obesity was suggested to be related to an enhanced
inflammatory environment associated with a greater
mobilization of endothelial progenitor cells and
reduced activation of the immune system (11). In
addition, another investigation in 29 morbidly
obese individuals with various traditional cardiovas-
cular risk factors, including the metabolic syndrome
(7), demonstrated that carotid-femoral pulse-wave
velocity, as a reflection of arterial stiffness, was only
mildly elevated. Interestingly, elevations in hsCRP
were inversely related to pulse-wave velocity, when
the opposite might have been expected (9,10).
Contrary to common opinion, therefore, metaboli-
cally triggered chronic microinflammation in severe
obesity may be associated with preserved flow-
mediated vasodilation and relatively low arterial
stiffness than was assumed previously. In this direc-
tion, the results of the current study provide first
evidence that increases in leptin and hsCRP plasma
levels correlated positively with altered and
endothelium-related MBF responses to CPT in
MOB subjects. Arterial increases in leptin concen-
trations and a metabolically triggered systemic in-
flammation, therefore, confer some beneficial ef-
fects on coronary endothelial function against
adverse effects of body fat on the endothelium in
MOB subjects. On multivariate analysis, increases
in hsCRP plasma levels remained independently
associated with the CPT-induced change in MBFs,signifying in particular inflammatory factors to
mediate direct protective effects on the coronary
endothelium in MOB subjects. Visceral adipose
tissue is characterized by an infiltration of macro-
phages, which have been demonstrated as a major
source of inflammatory cytokines such as tumor necrosis
factor-alpha, interleukin-6, and interleukin-10 in obesity
(1). For example, increases in anti-inflammatory
interleukin-10 have been shown to protect vascular
endothelial function by reducing increases in super-
oxide formation within the arterial wall in an
experimental model (17). Also clinical studies lend
further evidence of a potential vascular protective
role of interleukin-10 (18,19). If interleukin-10
serum levels were increased in CAD patients with
elevated CRP plasma levels, no impairment of
acetylcholine-stimulated forearm blood flow re-
sponse was noted (18). This reported preservation
of endothelium function in the presence of
inflammatory-triggered increases in interleukin-10
plasma levels in CAD patients (18) might also
provide a mechanistic link between a better clinical
outcome after acute coronary syndromes and re-
duced increased risk associated with elevated CRP
plasma levels (19). Because we did not measure
interleukin-10 plasma levels and other parameters
potentially involved in the adipose tissue–triggered
inflammatory process, further investigations are cer-
tainly needed to identify the exact mechanism of
the inflammatory response mediating protective
effects on the coronary endothelium in MOB.
C O N C L U S I O N S
Contrasting associations of altered coronary endo-
thelial function with increases in AEA, leptin, and
hsCRP identify and characterize OB and MOB as
different disease entities, rather than as a simple
continuation of increases in body weight, affecting
coronary circulatory function.
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